Trial Profile
The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2011
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myeloproliferative disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Incyte Corporation
- 29 Mar 2011 New trial record